Therapeutics News and Research

RSS

Cocrystal receives $733,438 in grants from QTDP program

Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.

4 Nov 2010

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.

4 Nov 2010

Regulus receives $488,989 grant under QTDP program

Regulus Therapeutics Inc. announced today that it has been awarded two grants totaling $488,989 under the Federal government's Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

InVivo receives $244,000 in grant funding under QTDP program

InVivo Therapeutics a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has been awarded $244,000 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010

CTI granted additional 180 days to regain compliance with NASDAQ minimum bid price rule

Cell Therapeutics, Inc. today announced that The NASDAQ Stock Market has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.

3 Nov 2010

BioCryst receives $1.1 million in grants under QTDP program

BioCryst Pharmaceuticals, Inc. today announced that the Company had been awarded $1.1 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the Company's clinical programs for peramivir, BCX4208 and forodesine, as well as the pre-clinical BCX4161 kallikrein inhibitor and JAK inhibitor programs.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV). These new data were presented today at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) international meeting in Boston, Massachusetts.

3 Nov 2010

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

ImmunoGen, Inc. a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.

3 Nov 2010

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).

3 Nov 2010

Waters launches new program to support scientific innovation

Waters Corporation today launched a new program to support scientific innovation in the fields of health and life science research, sports science, food safety, clinical research and environmental protection.

3 Nov 2010

Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients

Nile Therapeutics, Inc. a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced results of its Phase 2 study evaluating its lead compound CD-NP in patients with acute decompensated heart failure (ADHF) and mild to moderate renal insufficiency. Study results demonstrated that multiple doses were characterized as well tolerated with favorable drug activity in this acute patient population.

3 Nov 2010

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

2 Nov 2010

NPS third quarter net loss increases to $15.7 million

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the third quarter 2010.

2 Nov 2010

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Pain Therapeutics, Inc. announced today that it has been awarded over $2,000,000 in research grants by the U.S. government. These grants are planned to support the Company's on-going biomedical research for nervous system disorders and oncology. Pain Therapeutics expects to receive funding from these research grants now through the end of 2011.

2 Nov 2010

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

Therapeutics News and Research

Cocrystal receives $733,438 in grants from QTDP program

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

Regulus receives $488,989 grant under QTDP program

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

InVivo receives $244,000 in grant funding under QTDP program

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

CTI granted additional 180 days to regain compliance with NASDAQ minimum bid price rule

BioCryst receives $1.1 million in grants under QTDP program

Immunomedics product candidates, technologies receive recognition from QTDP program

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Waters launches new program to support scientific innovation

Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

NPS third quarter net loss increases to $15.7 million

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Celldex third quarter net loss increases to $9.1 million

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News